Claim OwnershipMAP - Market Access Podcast
Subscribed: 31Played: 443
Subscribe
© Copyright 2026 Dr. Stefan Walzer
Description
Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.
MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.
The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.
MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.
The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.
121 Episodes
Reverse
In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes — drawing on 18 years of leadership and a shared love of ice hockey.They discuss why trust and psychological safety are the foundation of any high-performing team, how role clarity and shared accountability turn a group of individuals into a unit, and why talent alone never wins — culture does. Along the way, Dr. Maurice shares the analogies he uses to make leadership tangible, from ships in a storm to aligned waves. A must-listen for leaders in pharma, market access, and beyond.Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don't forget to rate it and the podcast!MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/#MarketAccess #Leadership #PharmaLeadership #HighPerformingTeams #WinningMindset #CellTherapy #Pharma #IceHockey #marketaccesspodcast
Everyone wants AI to click the button for them — the real question is whether you still need to click it at all. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Seye Abogunrin, a health economist at Roche, Switzerland, to move AI in market access from experimentation to execution.They explore where AI adds real value today — drafting dossier text, screening titles and abstracts, extracting data from full-text papers — and why out-of-the-box prompting isn't enough. Seye makes the case that AI delivers strong first drafts, not submission-ready evidence, and that the human must stay "in the lead" for scientific rigor and credibility. They also unpack the real blockers at scale — change management, compliance, and data leakage — and why fully leveraging AI may mean overhauling our processes, not just speeding them up. The conversation also looks at how to identify the use cases that are genuinely worth scaling, rather than adopting AI for the sake of it. And as AI becomes more capable, the bigger opportunity may be to rethink how market access work gets done — not simply to make existing processes faster.Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don't forget to rate it and the podcast!MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #ArtificialIntelligence #AI #AIinHealthcare #HEOR #EvidenceSynthesis #HTA #DigitalHealth #MAPPodcast #marketaccess #marketaccesspodcast
By the time most health economists get pulled in, the recipe is already set. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist and Founder of TOWWERS — to make the case for moving early health economics upstream.The conversation reframes value as more than a financial number: the combination of clinical relevance, economic relevance, and affordability, aligned early across the "five Ps" — patients, prescribers, policymakers, payers, and producers. Björn and Julie explain why early models should be deliberately simple, built to test scenarios and surface the strongest value signals rather than chase false precision, and why embracing uncertainty is a feature, not a flaw. They also tackle the implementation risk too often ignored — illustrated by a CAR-T case in Quebec where it took a full year to treat the first patient after approval — and why an early "no-go" can be just as valuable as a green light.LinkedIn: Dr. Björn Schwander https://www.linkedin.com/in/bjoern-schwander-phd-672040b/Julie Frappier https://www.linkedin.com/in/julie-frappier-b5642a3/#MarketAccess #HealthEconomics #HEOR #EarlyModeling #RealWorldEvidence #HealthEconomicModeling #HTA #ValueBasedHealthcare #Reimbursement #MedTech #DigitalHealth #mAxInsights #marketaccesspodcast
1This is a repost of a popular episode of MAP - Market Access Podcast, from March 1st 2025.In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and the future of healthcare data regulation.Learn more about how data privacy laws create barriers for cross-border studies, delaying access to life-saving treatments, and how companies can navigate these hurdles and optimize market entry strategies. Can Europe find a balance between data privacy and innovation? Tune in to explore the challenges, solutions, and what’s next for healthcare in the EU.Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don't forget to rate it and the podcast!MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/#GDPR, #MarketAccess, #Real-WorldEvidence, #HealthcareData, #Pharma, #MedTech, #Cross-BorderStudies #mAxInsights #marketaccess #marketaccesspodcast
When Bern sets a price, Washington now listens. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Marcel Boller, Pharma and Medtech Expert and Partner at Werder Viganò in Zurich, to unpack why Swiss pricing reform has shifted from a reimbursement question into an industrial policy one.With Switzerland now in the US "Most Favored Nation" (MFN) reference basket, every price negotiated with the BAG (Swiss Federal Office of Public Health) signals straight to US payers. They discuss why fast Swissmedic approvals are undercut by slow reimbursement negotiations, and how the "local matador" concentration of power at the BAG leaves Switzerland without an independent HTA function. The Lilly Mounjaro case says it all: frozen for nearly two years, then listed on 1 January 2026 — just weeks after an MFN deal in the US.Yet Marcel's bottom line is optimistic: few countries can truly afford a high-quality healthcare system — and Switzerland could turn that into global leadership on patient access.LinkedIn: Dr. Marcel Boller (https://www.linkedin.com/in/marcel-Boller-/)Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don't forget to rate it and the podcast!MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #HTA #MFN #Switzerland #Swissmedic #PharmaPolicy #PricingAndReimbursement #PatientAccess #MostFavoredNation #mAxInsights #marketaccesspodcast
Comments
Download from Google Play
Download from App Store
United States